Bharat Biotech submits clinical trial data for paediatric vaccine to DCGI

The vaccine maker added that Covaxin is the first Covid-19 vaccine to be tested in the 2-6-year age group

The wait for a paediatric Covid-19 vaccine for children over two years may soon be over if India’s drug regulator decides to approve Bharat Biotech’s Covaxin for use in children.

The Hyderabad based vaccine maker has already submitted data from phase-2 and 3 clinical trials to the Drugs Controller General of India (DCGI) for review.

The company confirmed the development.

“Covaxin Clinical trials data of 2-18 years age group has been submitted to the Central Drugs Standard Control Organisation (CDSCO),” the company said.

The vaccine maker added that Covaxin is the first Covid-19 vaccine to be tested in the 2-6-year age